Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
LovedBy and Dexcom Announce Partnership to Help Adolescent Diabetes Patients
LovedBy, a technology and consultancy business that exists to improve the lives of people, their […]
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Certain People with Early Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration […]
NHS Delivers Over Three Million COVID Boosters in First Month
More than three million top up COVID-19 jabs have been delivered in just four weeks, […]
Lateral Flow Tests to be Introduced for Vaccinated International Arrivals
Eligible fully vaccinated passengers arriving in England from countries not on the red list can […]
Roche Announces PathAI Collaboration for Artificial Intelligence-based Digital Pathology Applications for Improved Patient Care
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, […]
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Topelia Australia Launches US$25M Series A Call for COVID-19 ATT Ziverdox
Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in […]
AZD7442 Reduced Risk of Developing Severe COVID-19 or Death in TACKLE Phase III Outpatient Treatment Trial
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca‘s AZD7442, a […]
FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia
Today, the U.S. Food and Drug Administration approved Rethymic for the treatment of pediatric patients […]
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more